Here are the numbers If we don't open until after the merger, here are some numbers.
The current 5.5 cent shareprice would equate to 82.5 cents after the x 15 consolidation. With roughly 53,313,000 shares fully diluted post-consolidation, that would make the market cap of the new company approximately $44M at a shareprice of 82.5 cents.
Now the question is, what will the new company be valued at by the market? Avisa has always been private, so we don't know what it's value is. Can their ABT device be disruptive technology that will be in high demand, especially if the company indicates it can detect Covid-19?
I also wonder if this funding is still available to them now that they are a publicly trading company outside of the US? This article was from 7 months ago.
https://innovations.unm.edu/unm-startup-avisa-pharma-to-go-public-on-toronto-exchange/